Thomas Patrick JR Joyce, a director at $ROP, bought 1,400 shares of the company on 02-06-2026 for an estimated $501,844. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings of this class of stock by approximately inf%. Following this trade, they now own 1,400 shares of this class of $ROP stock.
$ROP Insider Trading Activity
$ROP insiders have traded $ROP stock on the open market 14 times in the past 6 months. Of those trades, 4 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $ROP stock by insiders over the last 6 months:
- LAURENCE NEIL HUNN (President and CEO) has made 2 purchases buying 10,000 shares for an estimated $4,522,310 and 7 sales selling 30,000 shares for an estimated $13,307,176.
- JASON CONLEY (EVP, Chief Financial Officer) sold 6,000 shares for an estimated $2,673,390
- AMY WOODS BRINKLEY purchased 1,200 shares for an estimated $540,855
- THOMAS PATRICK JR JOYCE purchased 1,400 shares for an estimated $501,844
- ROBERT D JOHNSON has made 0 purchases and 2 sales selling 400 shares for an estimated $210,158.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ROP Hedge Fund Activity
We have seen 591 institutional investors add shares of $ROP stock to their portfolio, and 692 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 2,265,012 shares (-43.9%) from their portfolio in Q3 2025, for an estimated $1,129,538,834
- VANGUARD GROUP INC added 1,384,656 shares (+12.5%) to their portfolio in Q4 2025, for an estimated $616,351,925
- WELLINGTON MANAGEMENT GROUP LLP removed 1,365,565 shares (-72.5%) from their portfolio in Q3 2025, for an estimated $680,993,609
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,243,363 shares (-28.8%) from their portfolio in Q3 2025, for an estimated $620,052,694
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 819,939 shares (+71.7%) to their portfolio in Q3 2025, for an estimated $408,895,379
- D. E. SHAW & CO., INC. added 663,254 shares (+306.1%) to their portfolio in Q3 2025, for an estimated $330,758,137
- JPMORGAN CHASE & CO added 610,089 shares (+62.5%) to their portfolio in Q3 2025, for an estimated $304,245,283
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ROP Revenue
$ROP had revenues of $2B in Q3 2025. This is an increase of 14.33% from the same period in the prior year.
You can track ROP financials on Quiver Quantitative's ROP stock page.
$ROP Analyst Ratings
Wall Street analysts have issued reports on $ROP in the last several months. We have seen 6 firms issue buy ratings on the stock, and 3 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 01/28/2026
- Mizuho issued a "Underperform" rating on 01/28/2026
- JP Morgan issued a "Underweight" rating on 01/28/2026
- Barclays issued a "Underweight" rating on 01/28/2026
- Citigroup issued a "Buy" rating on 01/28/2026
- Piper Sandler issued a "Overweight" rating on 11/20/2025
- Jefferies issued a "Buy" rating on 10/24/2025
To track analyst ratings and price targets for $ROP, check out Quiver Quantitative's $ROP forecast page.
$ROP Price Targets
Multiple analysts have issued price targets for $ROP recently. We have seen 14 analysts offer price targets for $ROP in the last 6 months, with a median target of $478.5.
Here are some recent targets:
- Joe Ritchie from Goldman Sachs set a target price of $440.0 on 01/29/2026
- Terry Tillman from Truist Securities set a target price of $550.0 on 01/28/2026
- George Kurosawa from Citigroup set a target price of $450.0 on 01/28/2026
- Brad Reback from Stifel set a target price of $385.0 on 01/28/2026
- Brett Linzey from Mizuho set a target price of $365.0 on 01/28/2026
- Stephen Tusa from JP Morgan set a target price of $397.0 on 01/28/2026
- Deane Dray from RBC Capital set a target price of $398.0 on 01/28/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
